Basil T Darras
Overview
Explore the profile of Basil T Darras including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
205
Citations
6215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumari P, Sullivan L, Li Z, Parker Conquest E, Cornforth E, Jayakumar R, et al.
Nat Commun
. 2025 Mar;
16(1):2158.
PMID: 40044661
Chronic kidney disease (CKD) and the genetic disorder myotonic dystrophy type 1 (DM1) each are associated with progressive muscle wasting, whole-body insulin resistance, and impaired systemic metabolism. However, CKD is...
2.
McGrattan K, Graham R, Mohr A, Miles A, Allen J, Ochura J, et al.
J Neuromuscul Dis
. 2025 Feb;
12(1):22143602241308762.
PMID: 39973456
Background: Spinal Muscular Atrophy (SMA) is a progressive neuromuscular disorder that in its most severe form, causes profound swallowing deficits. There remains a paucity of research systematically elucidating the biomechanical...
3.
McMillan H, Baranello G, Farrar M, Zaidman C, Moreno T, Waele L, et al.
Neurology
. 2025 Jan;
104(2):e210268.
PMID: 39804575
Background And Objectives: Safety and efficacy of IV onasemnogene abeparvovec has been demonstrated for patients with spinal muscular atrophy (SMA) weighing <8.5 kg. SMART was the first clinical trial to...
4.
Morton S, Costain G, French C, Wakeling E, Szuto A, Christodoulou J, et al.
Neurology
. 2024 Dec;
104(1):e210106.
PMID: 39700446
Background And Objectives: Hypotonia is a relatively common finding among infants in the neonatal intensive care unit (NICU). Consideration of genetic testing is recommended early in the care of infants...
5.
Rovira-Moreno E, Abuli A, Munoz-Cabello P, Codina-Sola M, Bailles E, de Lemus M, et al.
Genet Med Open
. 2024 Dec;
1(1):100825.
PMID: 39669251
Spinal muscular atrophy (SMA) is a prevalent severe genetic condition that follows an autosomal recessive inheritance pattern. Over the last decade, advances in innovative therapies have improved the course of...
6.
Schroth M, Deans J, Bharucha Goebel D, Burnette W, Darras B, Elsheikh B, et al.
Neurol Clin Pract
. 2024 Oct;
15(1):e200374.
PMID: 39399564
Background And Objectives: Spinal muscular atrophy (SMA) is an autosomal recessive disorder caused by biallelic variants of the gene () that affects approximately 1 in 15,000 live births. Availability of...
7.
Coratti G, Bovis F, Pera M, Civitello M, Rohwer A, Salmin F, et al.
Eur J Neurol
. 2024 Oct;
31(12):e16517.
PMID: 39392101
Background And Purpose: Spinal muscular atrophy (SMA) is a genetic disorder caused by SMN1 gene mutations. Although studies on available disease-modifying treatments have reported their efficacy and safety, long-term natural...
8.
Coratti G, Civitello M, Rohwer A, Albamonte E, Montes J, Glanzman A, et al.
Neuromuscul Disord
. 2024 Sep;
44:104449.
PMID: 39299818
The Revised upper limb module (RULM) has been increasingly used in clinical trials and in clinical settings. The aim of this study was to use the 'shift analysis' to assess...
9.
Crawford T, Day J, De Vivo D, Krueger J, Mercuri E, Nascimento A, et al.
Front Neurol
. 2024 Aug;
15:1419791.
PMID: 39105058
Background And Purpose: At 12 months in the phase 2 TOPAZ study, treatment with apitegromab was associated with both an improved motor function in patients with Type 2 or 3...
10.
Coratti G, Civitello M, Rohwer A, Salmin F, Glanzman A, Montes J, et al.
Neuromuscul Disord
. 2024 Jun;
41:42-50.
PMID: 38936290
Several studies have shown the efficacy of new disease-modifying therapies in slowing down type II SMA progression using the Hammersmith Functional Motor Scale Expanded (HFMSE). This research aims to enhance...